Wiley, the world leader in trusted content and research intelligence for the advancement of scientific discovery, innovation, and learning, today announced its 2026 release. Mass spectrum of designer drugsis an important GC-MS spectral database used by forensic laboratories around the world to quickly identify illegal substances.
As the novel psychoactive substances (NPS) landscape continues to evolve, with an increasing number of synthetic cannabinoids, metabolites, fentanyl analogs, pharmaceuticals and metabolites, derivatives, and other emerging compounds, laboratories rely on continuously updated reference data to keep pace.
The latest release includes updates to ensure comprehensive and up-to-date support for forensic, toxicology, and drug surveillance workflows.
- Addition of over 700 new mass spectra
- Over 400 new and unique compounds across key NPS categories including fentanyl variants, synthetic opioids including xylazine and nitazene opioids, and cannabinoids
- The database currently displays 37,075 total mass spectra and 27,900 unique chemicals.
The 2026 release strengthens Wiley’s position as a leading source of trusted spectral intelligence, providing laboratories with the high-quality data they need to confidently, quickly and reliably identify emerging designer drugs. These enhancements directly support forensic and public health efforts as new hazardous substances continue to emerge. ”
Graeme Whitley, Senior Director, Data Science Solutions, Wiley
Designed for forensic and analytical laboratories
Designed for the unique demands of forensic and toxicology laboratories, Mass spectrum of designer drugs The database works with most major mass spectrometry systems and is also available as a KnowItAll database subscription. When combined with Wiley’s KnowItAll software, this database enables a powerful suite of advanced forensic tools, including drug classification models and Wiley’s patented MS Adaptive Search, to accelerate the identification and interpretation of both known and new compounds. These capabilities enable analysts to detect even new or unusual substances faster, more clearly, and more reliably, strengthening the role of databases for laboratories on the front lines of drug detection.
